Arana Therapeutics adds new face to clinical research team

BIO 2008, the world's largest conference for the biotechnology industry, is being held in San Diego from June 16. In our annual preview, we take a look at how the Australian sector is travelling.

Apollo aborts mission, investment fund licensed, biotechs move into Phase II trials and NuSep sorts its sperm.

With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.

Interest rates, evolutionary neighbours, antibodies get together and sorting sperm from the chaff.

Two local antibody therapeutics businesses have agreed to join forces.

Bionomics has some good news to take to BIO 2007 from preclinical trials of its candidate vascular disruption agent.

Last year wasn't the best on record for the Australian biotechnology industry but this year and the next look much more promising. Share prices are up, investors are showing more interest and there are a lot of good stories to tell and sell.

Peptech has released a new antibody technology platform called Synhumanisation.

The value of the Australian life science sector declined 3.5 per cent during the fourth quarter, ending 30 June 2006, according to the latest BioForum report from PricewaterhouseCoopers (PwC).

Brisbane cancer drug developer Progen Industries (ASX:PGL) managing director Lewis Lee has resigned, and the company has named his replacement -- one-time Monsanto executive Justus Homburg.